Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
The Clinical Utility of a Blood-Based Multitranscriptome Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
This observational or N/A phase trial investigates Gastroenteropancreatic Neuroendocrine Tumor and Lung Neuroendocrine Neoplasm and is currently completed. H. Lee Moffitt Cancer Center and Research Institute leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2021 — Jul 2024 [monthly]
Completed
-
Apr 2021 — Sep 2021 [monthly]
Completed
-
Feb 2021 — Apr 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 13 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Jun 2020 — Nov 2020 [monthly]
Active Not Recruiting
-
Jan 2020 — Jun 2020 [monthly]
Active Not Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting
-
Jul 2019 — Dec 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jul 2019 [monthly]
Recruiting
-
Nov 2018 — Apr 2019 [monthly]
Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lee Moffitt Cancer Center and Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .